MPC
47
3
PX
73
-6
CMS
58
-2
HUM
48
2
FTI
78
-3
MS
80
-3
LRCX
46
-2
CTSH
65
-3
TROW
51
-2
EMR
77
-2
WMB
68
-2
TRV
56
-2
GPC
40
2
KLAC
45
-4
DVA
72
-3
KSS
42
-3
HES
66
3
SLG
62
-4
EW
32
3
ADM
24
2
MPC
47
3
PX
73
-6
CMS
58
-2
HUM
48
2
FTI
78
-3
MS
80
-3
LRCX
46
-2
CTSH
65
-3
TROW
51
-2
EMR
77
-2
WMB
68
-2
TRV
56
-2
GPC
40
2
KLAC
45
-4
DVA
72
-3
KSS
42
-3
HES
66
3
SLG
62
-4
EW
32
3
ADM
24
2
Financhill
Back

Halozyme Therapeutics Quote, Financials, Valuation and Earnings

America's enemies are regrouping & it may sucker punch your savings

Click here to learn more.
Buy
69

HALO
Halozyme Therapeutics

Last Price:
53.92
Seasonality Move:
17.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.

Halozyme Therapeutics Price Quote

$53.92
-4.69 (-8%)
(Updated: November 14, 2024 at 5:55 PM ET)

Halozyme Therapeutics Key Stats

Buy
69
Halozyme Therapeutics (HALO) is a Buy
Day range:
$58.46 - $60.37
52-week range:
$33.15 - $65.53
Dividend yield:
0%
P/E ratio:
28.40
P/S ratio:
8.17
P/B ratio:
16.76%
Volume:
811.6K
Avg. volume:
1.4M
1-year change:
56.29%
Market cap:
$7.6B
Revenue:
$829.3M
EPS:
$3.02

How Much Does Halozyme Therapeutics Make?

Is Halozyme Therapeutics Growing As A Company?

  • What Is Halozyme Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.34%
  • What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0.72%

Halozyme Therapeutics Stock Price Performance

What Is Halozyme Therapeutics 52-Week High & Low?

Halozyme Therapeutics Price To Free Cash Flow

Is It Risky To Buy Halozyme Therapeutics?

Is Halozyme Therapeutics Cash Flow Positive?

  • What Is HALO Cash Flow From Operations?
    Cash flow from operations (TTM) is $403M
  • What Is Halozyme Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$222.4M
  • What Is Halozyme Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$300.5M

Halozyme Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    HALO return on invested capital is 22.41%
  • What Is Halozyme Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 20.54%
  • What Is HALO Return On Equity?
    ROE is a measure of profitability and is 156.62%

Halozyme Therapeutics Earnings Date & Stock Price

Halozyme Therapeutics Competitors

Halozyme Therapeutics Dividend Yield

Halozyme Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 72.13% 27.05%
Revenue: 34.28% 15.04%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 62.60
Upside from Last Price: 6.81%

Major Shareholders

  • How many HALO shares are owned by institutional investors?
    204.4M HALO shares are owned by institutional investors
  • How many HALO shares are owned by insiders?
    11.5M HALO shares are owned by insiders